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Abstract
The chapter includes a brief presentation of the types of skin cancer. The most aggressive
type of skin cancer, melanoma, is discussed from the point of view of incidence, molec-
ular, and immunohistochemical mechanism along with the most important biomarkers
for identification. Recent studies containing active phytocompounds with chemopre-
ventive activity pointing toward phytochemicals used for melanoma prevention and
therapy are reviewed. Modern physicochemical formulations for the enhancement of
bioavailability of some active phytochemicals with chemopreventive activity for malig-
nant melanoma are discussed.
Keywords: malignant melanoma, mechanism, biomarkers, active phytocompounds,
modern formulations
1. Introduction
Skin cancer, with its many forms, is one of the most prevalent diseases today. In the last
decades, there was a rising incidence in the reported cases of skin cancer and is estimated that
one out of three Caucasians may develop a type of skin cancer in their lifetime [1, 2]. There are
three common types of skin cancer, namely basal cell carcinoma (BCC), squamous cell carci-
noma (SCC), and melanoma. Basal and squamous cell carcinomas are also known as non-
melanoma skin cancer (NMSC) [1, 3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Melanoma and non-melanoma skin cancers represent the most common malignancies world-
wide [2, 3]. Wehner et al. indicated that approximately 30% of white people are likely to
develop NMSC in their lifetime as a result of increased exposure to ultraviolet radiation [4]. It
is considered that exposure to high doses of ultraviolet B radiation can cause basal cell
carcinoma, while squamous cell carcinoma can be triggered after a chronic exposure to UV
[2]. Melanoma in the first place and squamous cell carcinoma in the second place are tumor
types with a high risk of metastasis, while basal cell carcinoma rarely does. Usually, these
types of cancer affect people with white skin, blue eyes, and red hair [5]. Regarding gender,
men are more likely to develop a type of NMSC in their lifetime than women [1].
As already mentioned above, one of the most important risk factors for developing skin cancer
is considered exposure to ultraviolet radiation (UV) [6]. There are three types of UV radiation
depending on the wavelength: UVA, UVB, and UVC. UV radiation especially ultraviolet B
radiation is known to cause oxidative stress, inflammation, DNA damage, and apoptotic cell
death in the skin [6, 7]. UV exposure also determines immunosuppression and photoaging of
the skin [8]. People who use indoor tanning especially at an early age (before 25 years) are
exposed to a higher risk of developing a form of skin cancer in their lifetime [4]. Among UV
exposure, ozone depletion, genetics, and immune suppression are also incriminated in the
rising incidence of skin cancer [9]. Another factor considered responsible for skin cancer
growth is long-term exposure to arsenic, a class I human carcinogen found in industrial,
agricultural, and medicinal substances [10, 11]. PUVA therapy is a treatment used for severe
skin diseases which consists of psoralens (P) and exposure to ultraviolet A radiation (UVA).
PUVA may induce skin cancer by photomutagenicity and photoinduced immunosuppression.
It is important to evaluate the risk-benefit ratio before starting with the PUVA therapy
[10, 12, 13]. Exposure to ionizing radiation, inorganic metals, and polycyclic hydrocarbons are
also risk factors for skin cancer development [10].
1.1. Basal cell carcinoma
Basal cell carcinoma (BCC) is considered the most common type of skin cancer affecting people
worldwide [5, 3]. It develops in the basal layer of the skin, from keratinocyte stem cells.
Usually BCC appears de novo on hair-bearing skin, more often in adults. The most frequent
BCC is considered the nodular/nodulo-ulcerative type which is commonly found on the neck
and head. It looks like a red or pink papule with raised edges, telangiectasias, pearly appear-
ance, and central small ulcers. Nodular BCC develops slowly but in time it can invade the
tissue around it producing significant damage [14].
Exposure to high doses and intermittent UV radiation can trigger BCC [5]. Most cases of BCC
were reported in Australia and are mainly attributed to UV radiation [3]. UVB is considered
the most harmful environmental factor that can induce DNA mutations after exposure. BCC
can develop through alteration of p53 and PTCH1 tumor-suppressor genes.
In general, BCC is found on the arms, head, neck, or the back and is more prevalent in people
with light hair, blue or green eyes, and freckles. Other factors reported to increase the risk of
BCC are genetic conditions, ionized radiation, genodermatoses, exposure to chemical carcino-
gens, organic and inorganic solvents, and organophosphate compounds [14, 15]. In some cases
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of superficial BCC, human papillomavirus (HPV) is considered to be a risk factor in cancer
growth. Also, immunosuppression caused by other diseases is considered to have a role in
NMSC development [14].
There are various types of treatment options for BCC. The therapeutic approach depends on
the location and the size of the tumor. Also, it is important to know the morphology and
histologic subtype of the tumor and whether or not it has spread to nearby tissues. The most
common therapeutic option is surgical excision of the skin [14, 15]. In most of the cases, the
method is applicable if the lesion is less than 2 cm in diameter and is found in the trunk or
extremities. An advantage of surgical excision is that after surgery, the lesion can be histolog-
ically analyzed and the tumor subtype can be determined. Also, there are disadvantages of
using this method, including the possibility of infection and the presence of scars [14]. When
surgery is not possible due to tumor location or because it is locally advanced, radiation
therapy is an option [15]. The method can be used when the tumor is located on the ears, nose,
eyelids, and lips. Other therapeutical options include photodynamic therapy, cryosurgery
[14, 16], and topical therapies with imiquimod, an immune response modifier or 5-fluorouracil,
a pyrimidine analog [15]. It is important to properly treat BCC because it has a high tendency
to reappear if it remains untreated. Even if treated, in 18% of the cases, BCC will reappear in a
few years after treatment [14].
1.2. Squamous cell carcinoma
Squamous cell carcinoma (SCC) also arises from keratinocytes and is the second most common
type of skin cancer [17, 18]. SCC can be localized in the epidermis, known as in situ SCC, or it
can extend to the dermis or deeper in the skin, known as invasive SCC. UV exposure is the
main risk factor incriminated for SCC development. Cumulative high doses of UV radiation
are responsible for SCC evolution [17], also non-healing wounds or chronic lesions that were
linked with previous cases of chronic immuno-inflammation are associated with SCC [5]. SCC
is found at a higher prevalence at people who smoke, compared to non-smokers, probably as a
result of the immunosuppressive effects caused by smoking. Viruses, such as human papillo-
mavirus (HPV), human immunodeficiency virus (HIV), or human herpes virus (HHV), also
increase the risk for SCC. Exposure to chemical agents, including arsenic and polycyclic
aromatic hydrocarbons, can lead in time to SCC. People with genetic disorders, such as
xeroderma pigmentosum and oculocutaneous albinism, are more likely to develop SCC [17].
This type of cancer is usually found in people older than 50 years and is located on the head
and neck, being more frequent in males, than in females [17]. Usually, it does not metastasize,
but when it does, the survival rate is poor, between 25 and 40% [18].
SCC treatment depends on the location of the tumor, the size, and whether or not it has
metastasized. For high-risk tumors, Mohs micrographic surgery (microscopically oriented
histographic surgery) is considered the best method, while for low-risk SCC, surgical excision
is the most common therapeutic option. In order to have a low recurrence rate, safety margins
must be also excised. They vary between 4 and 10 mm according to tumor size. Cryosurgery is
another surgical method used for small tumors [17, 19]. Nonsurgical treatments are also
effective therapies for SCC, namely radiation therapy, topical application of 5-fluorouracil
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and imiquimod, and photodynamic therapy. There are studies, which indicate that non-steroi-
dal anti-inflammatory drugs are useful in the prevention and treatment of SCC [17]. Other
drugs used rather in the prevention than in the treatment of SCC are retinoids. The results of
Tran et al. showed that the topical administration of retinoids neutralizes vitamin A depletion
induced by exposure to UVB radiation and thus has a beneficial role on recovery [20]. Recur-
rence rate is around 5 years after treatment, so it is important that the patients are closely
monitorized [17].
1.3. Melanoma
Melanoma is a melanocytic neoplasia, and it is thought to be the rarest form of skin cancer and
the most aggressive one [1]. It is considered that melanocytic nevi are precursors for mela-
noma. They are benign nevi, usually found in body areas exposed to the sun and can undergo
transformation due to several risk factors and then progress into dysplastic nevi, which can
further turn into melanoma [21].
In order to establish whether or not a melanocytic nevus has a malignant transformation, five
characteristics can be followed, also known as the ABCDE of melanoma. The first is Asymmetry
—usually a benign melanocytic nevus is symmetric; Border—the margins of the nevus are
irregular; Color—the pigmentation is not equable on the entire surface of the nevus; Diameter
—the melanocytic nevus is bigger than 6 mm, Evolution [1].
Exposure to UV radiation is considered one of the most important factors in melanoma
development. Among it, genetic conditions, multiple nevi, and exposure to some chemical
agents are incriminated as risk factors [22, 23]. People who have first-degree relatives with
melanoma are exposed to a higher risk in developing this type of skin cancer. Immunosup-
pression is also thought to have a role in melanoma growth. Other risk factors include the
exposure to some pesticides, such as parathion, carbaryl, maneb/mancozeb, and benomyl [23].
Commonly, melanoma appears on males older than 54 years and females older than 45 years
and is mostly found on the trunk, face, and ears. In the last years, the number of melanomas
found in women aged 15–24 has increased [23]. Indoor tanning is considered to have an
important role in this higher incidence rate [24].
There are different forms of melanoma, the most common being melanoma of intermittently
sun-exposed skin, acral (and mucosal) melanoma, lentigo maligna melanoma, and nodular
melanoma. Melanoma of intermittently sun-exposed skin is generally found in Caucasian
people and is related with BRAF mutations and melanocytic nevi. It affects more women than
men, and is located in the lower extremities and the trunk [22]. Acral (and mucosal) melano-
mas can appear in areas of the body that are not frequently exposed to UV radiation such as
the soles of the feet and the palms of the hands. This type is found in black people and is
associated with chromosomal aberrations [5, 22]. Lentigo maligna (solar) melanoma develops
after chronic exposure to UV radiation. It is found in people older than 60 years and is
correlated with genomic aberrations and the lack of BRAF mutations. Nodular melanoma is a
rapid growing tumor that can have pagetoid spread, commonly found in people older than 30
years [22].
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Melanoma has a high metastatic potential through lymphatic and vascular channels. Early
diagnosis is very important because in the early stages it can be removed surgically. In order to
reduce the risk of tumor recurrence, along with the tumoral tissue, part of the surrounding
normal structure is also removed. The American Academy of Dermatology recommends the
following excisional margins (cm) according to tumor thickness (mm) [1]:
When there is evidence of metastasis, systemic chemotherapy is used. Frequently used drugs
are cisplatin, mitomycin, doxorubicin, and temozolomide. Immunotherapies are also an
option for metastatic melanomas. This includes administration of interferon-alpha or inter-
leukin 2 [1].
Patients with high-risk melanomas must be physically monitored every 3 months for the first 3
years, considered the period when metastases are more likely to appear and thereafter bian-
nually or annually [22].
2. Melanoma: incidence, molecular, and immunohistochemical mechanism
2.1. Incidence and mortality of melanoma
From the total number of all skin cancer cases, melanoma represents less than 2%, nevertheless
being the major cause of death from skin cancer. Despite this steadily increasing incidence of
melanoma, the mortality caused by this pathology stabilized in the last 20 years, on the
strength of advances in medical care. At present, the survival rate of 5 years exceeds 90%,
being associated with the moment of diagnosis [25].
It was predicted that 73,870 patients would be diagnosed with this condition in 2015. The most
affected segment was the white people of non-Hispanic origin. According to American Cancer
Society, the incidence rates vary from 1 per 100,000 annual cases in blacks to 4 in Hispanics, and
25 in non-Hispanic whites. Although it can appear independently of age, usually the elders are
more affected by melanoma, being diagnosed at an average age of 62 years [25]. By the age of
50, women are more affected than men; however, by age 65 the incidence is two times higher in
men than in women, tripling by the age of 80. These disparities are pursuant to ultraviolet
radiation, either solar or artificial. During 1930, the incidence of melanoma was 1 in 1500
American people, reaching 1 in 68 in 2002. Through the years 2002–2012, the incidence
extended with 1.8% per year. This enhancement of new cases of melanoma is partially linked
to the development of new, modern, diagnostic methods, and also to the rising of the average
life expectancy [25, 26].
Tumor thickness (mm) Excisional margins (cm)
in situ melanoma 0.5
<1.0 1.0
1.0–4.0 2.0
>4.0 ≥2.0
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In the US, during the year 2015, there were estimated 73,870 new cases of melanoma from
which 42,670 cases were in male and 31,200 in female. The total melanoma deaths in US, in
2015, reached 9940, whence 6640 cases in men and 3300 in women. In the State of California,
the total number of new melanoma cases reaches the upper limit (8560 cases), being followed
by Florida (5480 cases), while the minimum was observed in the District of Columbia (80
cases), followed by Alaska (100) [27].
In Europe, 100,000 new cases of melanoma were diagnosed during 2012, mostly in the central
and eastern part. The incidence of melanoma deaths was high in these regions of Europe
(36%); from a total of 22,000 deaths, 8000 cases were found in the Central and Eastern Europe.
However, the most cases of melanoma in Europe were in the Nordic regions and the Nether-
lands [28].
A recent study has compared the incidence and mortality rate in 11 countries from Europe:
Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Malta, Romania, Serbia,
Slovenia, and Turkey. Regarding the distribution of incidence upon age and sex, it was observed
that younger females and males had the same incidence rates, although it increased in middle-
aged and older men in comparison with females from the same category. The incidence rate of
melanoma was increased in most of the countries, the higher trend concerning the young people
(25–49 years) being observed in Slovenia, though in men aged 50–69, the incidence was impor-
tant in Slovenia, Slovakia, Bulgaria, and Serbia. After the age of 70, the rate was raised in men,
independently on the level of the incidence in the country. In women, the rate of melanoma was
increased in most regions of Europe, especially in Slovenia, whatever the age. For 50–69 aged
females, the incidence was higher in Bulgaria and Romania, while for women older than 70
years, a greater incidence in Serbia and Slovakia was remarked. For this category of women, the
incidence was also significant in Bulgaria, Croatia, and the Czech Republic. Regarding the
melanoma mortality rates in the 11 countries of Europe previously mentioned, men were more
affected than women in most countries. In younger groups, the mortality rate was non-signifi-
cantly decreased, in both men and women. Men of middle and older age had a relevant
mortality in Serbia. Also, the elders were affected in Turkey and Czech Republic. On the other
hand, women aged 50–69 had elevated rates of mortality in most countries, particularly in
Slovenia. The mortality increased with age, mainly in Serbia and Slovenia [29].
2.2. Molecular and immunohistochemical mechanism in melanoma
From the embryonic neural crest cells, throughout development, melanoblasts are first taken
into dermis, and then these precursors migrate toward the epidermis to settle in its basal
epithelial layer, on the basal lamina. Melanoblasts arise into dermis by 11 weeks. Melanin
pigment is produced at around 12 weeks [30].
Differentiated melanocytes are hold tightly in the basement membrane, when they arrive in
contact with keratinocytes. At higher epidermal layers, they are unable to survive, unless
turned into nevi or melanomas. Keratinocytes play an important role in the maintenance of
melanocytes homeostasis. The impairment of this homeostasis affects the epidermal melanin
unit, giving rise to an unceasing proliferation of melanocytes. It is presumed that melanoma
cells get rid of the keratinocytes control by several mechanisms: (a) down-regulation of some
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molecules (like E-cadherin) that play a role in their communication and adhesion to
keratinocytes; (b) up-regulation of certain molecules that participate in cell signaling signif-
icant for melanoma-melanoma and melanoma-fibroblast interplays, like N-cadherin, zonula
occludens protein-1, and MCAM (melanoma cell adhesion molecule); and (c) impaired expres-
sion of several proteins that bind the extracellular matrix with the repercussions for the
retention into the basement membrane [31, 32].
Recent studies revealed the up-regulation of CCN3 protein in melanocyte-keratinocyte co-
culture, influencing some important characteristics in the physiology of melanocytes. This
matricellular protein is overexpressed in some malignant diseases being related to the evolu-
tion of prostate cancer, carcinoma of renal cells, and Ewing's sarcoma; moreover, its expression
is linked to the differentiation of tumors in rhabdomyosarcoma and cartilage malignancies
[33–35]. Depending on the type of cancer, CCN3 influence divergently the genesis of tumor.
Therefore, in gliomas it manifests antiproliferative effects, as well as in chronic myeloid leuke-
mia cells. By contrast, it stimulates the invasion of Ewing's sarcoma cells [36, 37]. Regarding
the effects of CCN3 on melanocytes, it reduces their proliferation and is essential for the
melanocyte network organization [38]. In addition to this, it enhances the adherence of mela-
nocytes to the type-IV collagen from basement membrane. Studies in vivo show that CCN3
overexpression is associated with an extremely attenuated invasion of melanoma cells,
through the inhibition of MMP (matrix metalloproteinase) expression [31, 39].
The progression of melanoma comprises five distinct phases. First of all, hyperplasia of melano-
cytes gives rise to nevi; these can be acquired or congenital. The second phase is characterized by
dysplastic nevi along with cytological and architectural abnormality. The third one corresponds
to radial growth phase (RGP) melanoma, distinguished by the presence of tumor cells within the
epidermis, or their invasion through the superficial dermis, having a reduced ability to spread
from the primary site. The last stage is the vertical growth phase (VGP), which is featured by the
profound invasion of tumor cells into the dermis and hypodermic tissue, augmenting the
systemic dissemination risk. Lastly, metastasis occurs, being the most advanced phase of this
condition, as a result of the altered homeostasis in the skin. The impaired mechanisms of
homeostatic control determine the development of melanoma, since these mechanisms control
the proliferation of cells, as well as their differentiation and apoptosis [33, 41].
Throughout the development stages of melanoma, CCN3 protein expression is down-regu-
lated. Immunohistochemical techniques performed on melanoma cells evidentiated the
inversely proportional interdependence between CCN3 expression and tumor dimension.
The transduction of CCN3 in progressive melanomas inhibited the activity of matrix
metalloproteinases MMP 2 and 9, resulting in an intense reduction of tumor invasion. Hence,
the absence of CCN3 expression in melanomas is related to an invasive phenotype [31].
Melanomas can appear from melanocytes that have the role in the production of melanin
pigment, and also in its storage and distribution to keratinocytes. There are other melanomas
that arise from nevi, particularly dysplastic or giant congenital nevi. Melanomas are divided
into four clinic-histological types: superficial-spreading melanoma, nodular form, lentigo
maligna, and acral lentiginous type. Different factors are involved in the development of
melanoma, such as genetic triggers, methylation of DNA, acetylation, or milieu factors [40, 41].
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Impairment in tumor-suppressor genes such as mutation, deletion, translocation, or activation of
proto-oncogenes has a significant role in mutagenesis. Mutation or deletion of CDKN2A anti-
oncogene and CDK4 proto-oncogene is related to the development of familial melanoma, which
constitute 8–12% of total melanomas [42]. This type of melanoma is characterized by an abnor-
mal regulation of cell cycle by cyclin-dependent enzymes. In this case, the 9p21 chromosome has
a germline mutation in the locus of CDKN 2A gene, affecting two proteins p16 and p14 or Arf
that have a suppressive role. The p16 protein has an inhibitory effect on cyclin D/CDK4 and
CDK6, influencing therefore pRB (retinoblastoma protein) which, through liberation of E2F, change
the G1 phase of cell cycle into S phase [43, 44]. It was discovered lately that E2F1 protein, as well,
manifests a suppressor function through p53 or p73. Between 10 and 30% of familial melanoma
cases are due to CDKN2A mutation. NRAS and p16 mutations are also incriminated in some
isolated cases of melanoma. Mutation of CDKN2A can lead to multiple melanomas. This alter-
ation seldom appears in actinic keratosis, skin carcinomas, and other types of cancers [45, 46].
The p14 protein, encoded by CDKN2A reading frame, affects the p53 protein through the
influence on other protein, Mdm2. The p14 deprivation lowers the activity of p53 [47]. Studies
taken on mice models have shown that p14 can determine apoptosis of oncogene-activated
melanocytes [48, 49].
It is known that pigmentation of the skin that depends on the amount of melanin is in direct
relation with the development of melanoma. It is 10 times more frequently in whites than in
blacks; however, people affected by albinism are exceptionally affected. The highly polymorphic
melanocortin 1-receptor gene (MC1R) situated on 16q24 chromosome controls sun sensitivity
[50, 51]. It codifies the transmembrane receptor coupled with G protein. The pituitary polypep-
tide POMC (pro-opiomelanocortin) is cleaved to give rise to different peptide hormones, including
MSH (melanocyte-stimulating hormone), that acts through this receptor, enhancing cAMP and
therefore stimulating tyrosinase enzyme activity. As a fact, keratinocytes can also produce these
molecules. The synthesis of dark eumelanin and yellow cysteine-abundant pheomelanin is aug-
mented by MSH. It was observed that people with MC1R variations evolve to earlier melanoma
[52]. New studies have revealed that MITF (microphthalmia-associated transcription factor) gene
found on 3p14 chromosome has a role in the promotion of melanocyte cell cycle progression [53].
3. The most important biomarkers for the identification of malignant
melanoma
In order to diagnose malignant melanoma, there are several methods and techniques that
when combined can give a certain degree of surety to the diagnosis.
As previously discussed, the first step in diagnosing malignant melanoma is the visual inspec-
tion of the lesion and the assessment of the well-known ABCDE signs (Asymmetry, irregular
Borders, uneven Color, large Diameter, Evolution) [54]. These findings are combined with
dermatoscopical inspection of the lesion in order to confirm or to infirm the naked eye observa-
tions. If these findings lead to a suspicion of malignancy, then most likely a wide-excision
surgery is performed and upon the assessment, a sentinel lymph node biopsy is also performed
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[55]. In order to establish a certain diagnosis, there are various sets of markers specific for this
type of cancer, which enable the obtaining of a definite diagnosis and/or the prognosis and
staging of the disease, which can be identified by several methods [56].
There are different types of biomarkers to investigate malignant melanoma such as the micro-
scopical markers identified upon the examination of the tumor and the immunohistochemical
biomarkers identified upon isolation from the tumor/tissue section. Another type of malignant
melanoma markers is the serological biomarkers that are identified from the peripheral blood
samples of the patients by various methods.
3.1. Microscopical biomarkers in malignant melanoma
Breslow thickness refers to the thickness of the tumor and was demonstrated to be the most
important prognostic histopathological factor. This parameter is of great importance and is
used to stage malignant melanoma [57].
Tumor ulceration is the loss of epidermal integrity of the melanoma and is used for staging
malignant melanoma and was linked to rapid tumor growth and metastasis [58].
The mitotic rate refers to the number of mitoses per square millimeter. A high mitotic rate is
correlated with high metabolic cell activity and predicts rapid tumor growth and metastasis.
Also, increased mitotic rate was linked with decreased survival [59].
3.2. Immunohistochemical and serological biomarkers in malignant melanoma
Immunohistochemical biomarkers
Biomarker type Significance/location Specificity/involvement in prognosis
2.1 HMB 45 (human
melanoma black 45)
Monoclonal antibody for the premelanosome
protein (Pmel antigen) [60]
Very specific for melanoma, especially for
primary lesions, not being able to identify other
types of tumors [61, 62]
2.2Melan A Antigen recognized by T cells 1 or MART-1
(membrane protein of melanosomes and
endoplasmic reticulum found in melanocytes,
melanoma, and endoplasmic reticulum)
[63, 64]
Higher sensitivity for primary melanomas
compared to metastatic ones [65]
2.3 S 100 Family of proteins expressed in Schwann cells,
melanocytes, glial cells, is involved in many
cellular functions such as the activation of cell
processes along the Ca2þ signal-transduction
pathway [66, 67]
Low specificity, used together with other
biomarkers [65]
2.4 Tyrosinase Oxidative enzyme involved in melanin
production in melanocytes and melanoma;
detected with T311 monoclonal IgG antibody
[68]
Elevated sensitivity for primary melanoma
than for later stage tumors [68]
2.5 Ki-67 Protein biomarker for cellular proliferation [69] Adjunctive diagnostic biomarker [70]
2.6 Nestin Filament protein associated with migration and
metastasis [71]
Advanced stages of the disease (T3 and T4) [71]
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Immunohistochemical biomarkers
Biomarker type Significance/location Specificity/involvement in prognosis
2.7 Vimentin Ectodermal, neural, and pancreatic progenitor
cell marker, overexpression in cancer [72]
Tumor growth, invasion, and poor prognosis
[72]
2.8 Chondroitin
sulfate proteoglycan 4
Located in melanocytes, promotes cell
adhesion, growth, migration, motility [65]
Invasion and metastasis [65]
2.9 EFGR (epidermal
growth factor
receptor)
BRAF transmembrane tyrosine kinase [73] Progression and metastasis [74]
2.10 P53 (cellular
tumor antigen p53)
Tumor suppressor “guardian of the genome”
(promotes cell cycle arrest, apoptosis,
senescence, and DNA repair) [75, 76]
Inactivated or functionally impaired in
melanoma [75]
Serological biomarkers
3.1 LDH (lactate
dehydrogenase)
Enzyme that converts lactate into pyruvate in
anaerobic conditions [77]
High levels are correlated with metastasis,
decreased survival rate, negative outcome after
treatment [77]
3.2 CRP (C-reactive
protein)
Nonspecific marker of inflammation, infection,
cancer [65]
Predictor for disease progression in high levels
[65]
3.3MIA (melanoma-
inhibiting activity)
Protein associated with in vitro increased
invasiveness, extravasation, and metastasis [77]
Elevated levels, marker for advanced stage (III
and IV) and poorer prognosis [77]
3.4 VEGF (vascular
endothelial growth
factor)
Protein that stimulates vasculogenesis and
angiogenesis [78]
Elevated levels linked to poor progression-free
survival [78]
3.5 BRAF Raf kinases family involved in RAF-MEK-ERK
signal transduction pathway (cell growth,
proliferation, and differentiation) [79]
BRAF mutation, BRAF-V600E, associated with
increased tumor thickness, ulceration, and
reduced survival [80]
3.6miRNA
(MicroRNAs)
RNA molecules involved in proliferation,
differentiation, stress responses, apoptosis
[77, 78]
Disease progression and risk of recurrence
[77, 78]
3.7 GM3 Ganglioside (glycosphingolipid) involved in
cell proliferation, differentiation, apoptosis,
embryogenesis, and oncogenesis [81]
Low levels (early stage) linked to invasive
proliferation; higher levels (late stage) linked to
cell migration and invasion [81]
3.8 OPN (osteopontin) Glycol-phosphoprotein implicated in reduction
of apoptosis, promotion of tumor growth,
tumor-promoting stromal cell in the bone
marrow [82]
Rapid melanoma growth, angiogenesis, and
aggressive metastasis [83]
3.9 IL-8 (interleukin-8) Chemokine produced by malignant cells [82] Associated with tumor burden, stage
of the disease, survival, and response to
therapy [82]
3.10 YKL-40 Heparin secreted during the late stages of cell
differentiation [84]
Overexpression associated with poor survival
[84]
3.11 CTC (circulating
tumor cells)
Cells from melanoma metastatic tumors [77] Linked to inferior survival; predictive marker
for selecting the systemic therapy [77]
3.12Melanoma-
initiating cells
Cancer stem cells [85] Can lead the specific targeted systemic therapy
[85]
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4. Recent studies concerning active phytocompounds targeting malignant
melanoma
Although synthesized to serve the plant in modulating its interaction with the environment,
many natural compounds act as drugs when used by humans by binding to various
enzymes and receptors. In the area of anticancer medications, it has been shown that about
75% of the medications are naturally derived or inspired [86]. Phytocompounds hold an
important potential in the chemoprevention and treatment of melanoma, including metas-
tasis [87, 88]. The main advantage of natural products relies in their multi-target activity,
with one compound being able to interact with multiple proteins and receptors. Anti-
melanoma activities have been pointed out for both phytocompounds from nutraceuticals
(polyphenols, polysaccharides, and carotenoids), as well as for highly active secondary
metabolite classes like the alkaloids or the terpenes. Additionally, there are a number of
crude extracts or enriched fractions with anti-melanoma actions, for which the active com-
pound(s) could not be singled out yet. A promising field in the actual usage of plant-
derived compounds is their synergistic activity when administered in combination with
synthetic anticancer medications [89].
4.1. Polyphenols
The potential of polyphenolic compounds (Figure 1) as anti-melanoma agents was recognized
as early as 1995, when Menon and coworkers found that orally administered curcumin,
catechin, and rutin significantly prolonged the life span of animals with experimental mela-
noma [90]. The anticancer potential of these food constituents is supported by epidemiological
studies [91]. Their general mechanisms of action may be summarized as follows: antioxidative,
photoprotectant, induction of apoptosis, and inhibition of angiogenesis. Antioxidative capaci-
ties are seminal for the protective activity against UV-induced oxidative stress [92]. The ability
to act as UV filters is related to the physiologic function of certain flavonoids present in
epicuticular waxes protecting the plant epidermis against UV radiation [93]. Apoptosis is
mainly promoted by polyphenols via regulation of Bcl-2 family proteins and caspase-3 activa-
tion, while the anti-migratory effects are mainly obtained by down-regulation of MMPs
expression.
Intensely researched polyphenols in the context on melanoma include flavonoids (quercetin,
apigenin, silymarin, genistein, catechins, anthocyanins, biflavonoids), curcumin, and resvera-
trol [94]. Quercetin (1), an abundant dietary flavonol, acts via all above-cited mechanisms. It
decreases the viability and promotes the apoptosis of ultraviolet UVB-irradiated B16F10 mel-
anoma cells by several mechanisms: it increases the levels of reactive oxygen species, depolar-
izes mitochondrial membrane potential, induces the imbalance of calcium homeostasis,
attenuates MEK-ERK signaling, and changes the ratio of Bcl-2, Bax, and Bim expression in
favor of cell death elicitation [95]. It offers photoprotection against melanogenesis through a
regulatory effect on the Nrf2-ARE pathway [96]. Furthermore, quercetin inhibits melanoma
cell migration in a setup of experimentally activated receptor tyrosine kinase c-Met, known to
be involved in the acquisition of metastatic phenotypes [97].
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Apigenin, a flavone from the point of view of chemical structure, offers an effective photoprotection
against UVA- and UVB-induced skin carcinogenesis [98], fights metastasis by preventing the
activation of MMP-2, MMP-9, VEGF, and Twist1 genes through down-regulation of STAT2
signaling [99], promotes apoptosis via caspase-3 and cleaved poly(ADP-ribose) polymerase
[100]. In addition, apigenin blocks the COX-2 pathway and increases terminal differentiation in
the epidermis [101].
Silymarin, a complex of flavonolignans from the achenes of milk thistle, is a natural product
known especially for its hepatoprotective, anti-oxidative and anti-inflammatory effects [102].
When applied locally, silymarin was able to inhibit carcinogenesis induced by UV-radiation
and to decrease tumor multiplicity and growth. It produces cell cycle arrest in melanoma cells
via inhibition of kinase activities of (MEK)-1/2 and RSK-2 [103], induces apoptosis and coun-
teracts metastasis via down-regulation of MMPs expression [104]. Silymarin is a prominent
inhibitor of Wnt/β-catenin translocation in melanoma cells, beside few other phytocompounds
Figure 1. Chemical structure of representative polyphenols targeting malignant melanoma. 1: quercetin, 2: (–)-epigallo-
catechin-3-gallate, 3: curcumin; 4: resveratrol.
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like the flavonoid fisetin, the triterpene lupeol, and the alkaloid tryptanthrin; aberrant Wnt
signaling occurs in one-third of melanomas [105].
Catechins are flavanols devoid of the 3-oxo group specific to other flavonoids; they may espe-
cially be found in woody plants like wine and the tea plant. Catechins as well as their esters with
gallic acid, in particular epigallocatechin-3-gallate (EGCG, 2), are the subject of intense research
in cancer prevention and treatment. In the field of anti-melanoma activities, the chemopreventive
effect of ECGC is mainly achieved by a photoprotective effect exerted through interleukin 12
induction followed by DNA repair, inhibition of angiogenesis, and the stimulation of cytolytic T
cells [106]. The proapoptotic effects are exerted by EGCG through down-regulation of inhibitory
proteins such as Bcl-2, D1, and cdk2, as well as the up-regulation of the proapoptosis protein
Bax. Important tumor-suppressor proteins (p16, p21, and p2) are induced by EGCG [107, 108].
More recently, the discussed polyphenol was shown to bind to the cell surface receptor 67LR,
overexpressed in melanoma [109]. As an agonist of 67LR, EGCG is able to suppress melanoma
tumor growth by activating a specific signaling pathway (cAMP/PKA/PP2A) via regulation of
miRNA-let-7b expression in melanoma cells [110]. Moreover, EGCG displays an excellent anti-
metastatic profile, reducing the number of lung metastases in mice [111]. Molecular targets in
this regard are COX-2, PGE2 receptors, the impairment of epithelial-to-mesenchymal transition
[112], reduction of angiogenesis promoters and down-regulation of MMP2 activity and ERK1/2
pathway [113].
Curcumin (3), an orange-colored constituent of turmeric rhizomes (Curcuma sp.), is an exten-
sively investigated compound with anti-inflammatory and anticancer activities. In human
melanoma cell lines (A375 and C8161), it reduces cell viability, has an antiproliferative effect
arresting mitosis at the transition of G2/M phase, suppresses cell invasion, and induces
autophagy [114]. The anti-metastatic effect was demonstrated in vivo using C57BL/6 mice; the
down-regulation of metalloproteinases and collagenases activities, modulation of integrin
receptors [115] and interference with the STAT3 pathway support this observation [116].
Resveratrol (4), a stilbene found mainly in grapes and Polygonum cuspidatum, inhibits mel-
anoma proliferation in vitro, arresting cell divisions at the G1/S transition and induces
apoptosis targeting Bcl-2-associated X protein, B-cell lymphoma 2, and caspases -9 and -3
[117]. Through the suppression of β-catenin and STAT3-pathway, resveratrol reduces the
levels of survivin, a protein which is essential for the survival of melanoma cells. Further-
more, the compound has anti-migratory activities mediated by the deactivation of the
proto-oncogenic Akt [118]. The low bioavailability of resveratrol triggered the obtainment
of several analogs, as well as the preference for the use of the natural pterostilbene having a
longer half-life [87].
4.2. Polysaccharides
The potential of polysaccharide fractions obtained from terrestrial and marine organisms in
cancer treatment receives an increasing attention. These compounds are potent immunomod-
ulators, leading to the release of cytokines which may play important roles in the defense
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against cancer [119]. Their main mechanism of action includes activation of natural killer cells,
induction of inflammatory caspases, and down-regulation of MMPs expression, but as a
general feature their mechanism of action is much less known than in the case of plant poly-
phenols. An important advantage of polysaccharides is their very low toxicity.
The sulfated and partially acetylated fucoidans from brown algae Coccophora langsdorfii
and Fucus evanescens, consisting of (1!3)- and (1!4)-linked α-l-fucopyranose residues, pro-
duced a significant inhibition of colony formation of SK-MEL-5 and SK-MEL-28 melanoma
cells [120].
Beta-glucans are constituents of cell walls in certain fungi, algae, and vascular plants such as
oat or barley. Oral administration of yeast-derived beta-glucan to mice inoculated with B16
murine melanoma cells significantly reduced tumor weight, pulmonary metastasis, and
survival rate. These effects are mediated by the activation of NK cells. An important finding
was that beta-glucan supplementation was devoid of hematopoietic toxicity, unlike chemo-
therapeutic drugs such as 5-fluorouracil [121]. Low-molecular-weight beta-glucan prepared
from oat decreased the cell viability of cancer cell lines Me45 and A431, while normal
keratinocytes were not affected. The cytotoxic effect was mediated by induction of caspase-
12 expression. This natural product had the advantage of a good solubility in water and a
low viscosity, in comparison with other glucans [122]. Polysaccharides from higher plants,
like raspberry fruits, have as well been shown to inhibit melanoma growth, and to have a
synergistic activity with docetaxel in vivo, reducing at the same time liver and kidney injuries
inflicted by the latter [123]. Pectins from corn demonstrated their ability to inhibit cancer cell
growth and metastasis by modulating specific markers such as galectin-3, VEGF, MMP-2
and MMP-9, and NF-κB [124].
4.3. Volatile oils
Volatile oils are complex mixtures of monoterpenes, sesquiterpes, aromatic compounds, and
their derivatives, which are produced by plants in order to protect themselves against patho-
gens, herbivores, or, on the contrary, to act as signals for pollinators and disseminators [125]. In
the search for innovative strategies in melanoma treatment, these natural products have as
well been investigated. The main mechanisms of action known so far are represented by
induction of apoptosis (via increasing the expression of p53 and caspase-3) and reduction of
angiogenesis with down-regulation of MMPs.
The volatile oil of the tea tree plant (Melaleuca alternifolia) and its main component terpinen-
4-ol (5) were evaluated in an experimental setting of human melanoma M14 WT cells and
M14 adriamycin-resistant cells. Concentration as low as 0.005–0.03% proved to induce apo-
ptosis, and conversely the resistant cell variant was more sensitive [126]. More recently,
Greay and coworkers [127] applied a topical formulation containing 10% tea tree oil and
found a significant delay in the growth of established subcutaneous B16-F10 melanoma,
while systemic toxicity was absent. The volatile oil of Tridax procumbens, a common annual
Natural Products and Cancer Drug Discovery224
Asteraceae in most tropical regions, displayed anti-metastatic effects by the inhibition of
lung nodule formation by B16F-10 cells in C57BL/6 mice. Furthermore, it induced apoptosis
increasing the expression of p53 and caspase-3 and reduced angiogenesis [128]. Curcuma
zedoaria volatile oil suppressed as well melanoma growth and lung metastasis, with the
down-regulation of MMPs [129].
4.4. Alkaloids
Alkaloids are nitrogen-containing plant metabolites with usually very intense pharmacologic
effects at even low dosages. Consequently, their safety profile is very different from the one of
compounds discussed above. The main compounds from this class, which are able to target
melanoma, include berberine, harmine, paclitaxel, and glycoalkaloids from Solanaceae. While
the number of reports on the anti-melanoma potential of alkaloids is rather scarce in compar-
ison with that of polyphenols, the mechanisms of action are well studied. The anti-migratory
properties of alkaloids in malignant melanoma have been the subject of a comprehensive
review [87]. Alkaloids may induce apoptosis via the inhibition of the Ras-signaling cascade at
various downstream points, blocking both PI3K/AKT and MAP/ERK pathways. Metastasis is
mainly counteracted by blocking the COX pathway and angiogenesis. NF-κB inhibition is as
well a target of anti-melanoma alkaloids.
Berberine, an isoquinoline alkaloid (6), occurs in several medicinal plants of the Berberidaceae,
Ranunculaceae, and Papaveraceae families [130]. While best known for antimicrobial, anti-
inflammatory, anti-hyperglycemic, and anti-hyperlipidemic effects [131], berberine is one of
the most active alkaloids in melanoma. It has been shown to inhibit kinases like PI3K, ERK,
and GSK3β [132]. Moreover, in combination with doxorubicin, it intensely reduces prolifera-
tion and increases apoptosis, effect demonstrated both in vitro and in vivo [133]. Berberine
inhibits the migration of melanoma cells via the reduction of COX-2/PGE2 receptors expres-
sion [134] and has anti-angiogenetic properties [135]. Harmine is an indole alkaloid contained
by only a few plant species, including Peganum harmala and Banisteriopsis caapi. While its ability
to bind monoamino-oxidase A and to elicit psychoactive effects is known since several
decades, the potential anticancer properties of this compound have only been explored in
recent years. In melanoma, it displays important anti-migratory effects through the inhibition
of NF-κB and other transcription factors (CREB, ATF-2) [136]; it reduces lung metastasis in
C57BL/6 mice and down-regulates the expression of pro-metastatic genes (MMP-9, ERK, and
VEGF) [137].
Paclitaxel is a pseudoalkaloid, first isolated from the bark of the Pacific yew (Taxus brevifolia),
approved for the clinical treatment of several solid tumors with poor prognosis including
melanoma [138]. It stabilizes microtubules, disrupting the dynamic equilibrium between free
and polymerized tubulin; as a consequence, cell division is arrested in the G2/M transition of
mitosis [139]. Additionally, paclitaxel has antiangiogenic effects, which are potentiated by
COX-2 inhibitors [140]. Disadvantages of this compound include its extreme hydrophobicity,
which could be overcome in modern nanoformulations, as well as drug resistance to paclitaxel
An Update On Natural Compounds and Their Modern Formulations for the Management of Malignant Melanoma
http://dx.doi.org/10.5772/67647
225
due to the induction of the efflux protein P-gp and unusual expression of class III isotype of β-
tubulin [139].
Glycoalkaloids from Solanaceae, including α-solanine and solamargine, displayed anti-
melanoma effects in recent reports. Interestingly, solamargine inhibited selectively the growth
of WM239 and WM115 melanoma cells, in comparison to benign WM35 cells. Cellular necrosis
occurred upon permeabilization of the lysosomal membrane, which triggered, in turn, the
extrinsic pathway of mitochondrial destruction. The intrinsic apoptosis pathway was as well
disrupted by this compound [141]. α-Solanine displays anti-proliferative effects, induces apopto-
sis, and suppresses melanoma cell invasion, mainly via the reduction of MMP-2 and MMP-9
activities. The potential of this compound in the treatment of metastatic melanoma is further
substantiated by the inhibition of JNK and PI3K kinases as well as the reduction of NF-κB
activity [142]. Two chemical structures of representative natural compounds targeting mela-
noma, other than polyphenols, are presented in Figure 2.
5. Modern physicochemical formulations for the enhancement of
bioavailability of selected active phytochemicals with chemopreventive
activity for malignant melanoma
Formulation development can be regarded as a determining aspect in the delivery of antineo-
plastic natural compounds due to their physicochemical properties, in particular water solu-
bility, which limit their bioavailability [143]. A variety of formulation strategies have been
reported highlighting the main challenges that arise in the development of optimized drug
delivery in the anticancer field [144], including skin cancer. The most studied natural antican-
cer compounds in terms of bioavailability improvement are different types of polyphenols
(curcumin, silymarin, and resveratrol) and alkaloids (paclitaxel). In Tables 1–4, we aim to
summarize the main reported attempts to increase the bioavailability of the above-mentioned
compounds through various modulations of their physicochemical parameters as well as
modern pharmaceutical formulations.
Figure 2. Chemical structures of representative natural compounds targeting melanoma, other than polyphenols.
5: Terpinen-4-ol, the major monoterpene in tea tree volatile oil, 6: Berberine, an intensely researched alkaloid.
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Curcumin formulations Components Method of application Indications/remarks Ref.
Curcumin þ piperine -curcumin
-piperine
Oral administration to male Wistar
rats (epilepsy model)
(2 g/kg curcumin, þ20 mg/kg
piperine)
20-fold higher curcumin bioavailability
compared to curcumin alone (piperine
decrease hepatic and intestinal
glucuronidation)
[145]
Curcuminoids (curcumin,
demethoxycurcumin, bis-
demethoxycurcumin) þ
Sesamin
Ferulic acid
Naringenin
Xanthohumol
(simultaneous
administration)
Curcuminoids micellar
solubilized þ
Sesamin
Ferulic acid
Naringenin
Xanthohumol;
Curcuminoids micellar
solubilized
2:2:1:1:1 (w/w):
-Curcumin powder: (82% curcumin þ16%
demethoxycurcumin þ2% bis-
demethoxycurcumin)
-sesamin
-ferulic acid
-naringenin
-xanthohumol
-95.1% Tween-80
-1.4% curcumin
-1.4% sesamin
-0.7% naringenin
-0.7% ferulic acid
-0.7% xanthohumol
-7% curcuminoid powder
(=6% curcumin)
-93% Tween-80
Oral capsule administered to
healthy humans (98 mg
curcuminoids, single dose)
8-fold increase in bioavailability;
73-fold increase in bioavailability;
88-fold increase in bioavailability
[146]
Liquid micelles of curcumin
Micronized powder of
curcumin
Native curcumin powder
- 7% curcumin powder (equivalent to 6%
curcumin)
-93% Tween-80
-25 % curcumin powder
-58.3% triacetin
-16.7% panodan
-82% curcumin
-16% dimethoxy-curcumin
- 2% bis-dimethoxy-curcumin
Oral administration to healthy
humans (500 mg curcuminoids,
single dose)
277-, 114-, 185-fold increase in bioavailability
in women/men/all subjects compared to
native curcumin powder;
14-, 5-, 9-fold increase in bioavailability in
women/men/all subjects compared to native
curcumin powder;
Women absorbed curcumin much more
efficiently than men
[147]
Curcumin nanosuspension -10% curcumin
- 2% polyvinyl alcohol
-88% water
Oral capsules administered to male
Wistar rats, 100 mg/kg
Increased oral absorption and bioavailability -
> significant increased concentration in
selective organs;
-direct uptake from the gastrointestinal tract;
-increased permeability induced by
surfactants;
[148]
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Curcumin formulations Components Method of application Indications/remarks Ref.
-increased resistance to degradation and
elimination.
Sustained-release
formulation of curcumin
MicroActive® Curcumin (patented
formulation):
-25% micronized curcuminoids
-polyglycerol esters of fatty
acids
-medium-chain triglycerides
-hydroxypropyl-
methylcellulose
-sodium alginate
-microcrystalline cellulose
Oral capsules administered to
healthy humans, 500 mg curcumin
(single dose)
9.7-fold increase in bioavailability (test
period: 12 h)
[149]
Curcumin þ
phosphatidylcholine
Meriva®,
(patented complex of curcumin with soy
phosphatidylcholine):
-20% curcuminoid mixture
- 75% curcumin
- 15% demethoxycurcumin
- 10% bisdemethoxycurcumin
-40% soy phosphatidylcholine
-40% microcrystalline cellulose
Oral administration to male Wistar
albino rats, 340 mg/kg
Reduced curcumin concentration in the
gastrointestinal mucosa;
Significant increased plasma/liver levels
(compared to an unformulated curcumin);
Indications: Chemoprophylaxis intervention
studies targeting sites other than the
gastrointestinal tract
[150]
Curcumin
þ PVP
(polyvinylpyrrolidone)
þ cellulosic
derivatives
þantioxidant agents
CurcuWIN,
-minimum 20% curcuminoids
- PVP (polyvinylpyrrolidone)
- cellulosic derivatives
- antioxidant agents
Randomized, double-blind,
crossover human study in healthy
volunteers (hard gel capsules,
376 mg curcuminoids)
-45.9-fold increase in curcumin oral
absorption compared to unformulated
standard curcumin, 5.8-fold increase over a
phytosome formulation, 34.9-fold increase
over
(curcumin þ volatile oils
from turmeric rhizome)
formulation
[151]
Lipid based nanoparticles:
phospholipid vesicles/lipid-
nanospheres
Phospholipid vesicles:
-DMPC/SA/PEG-DSPE/curcumin
(molar ratio 10/1/0.06/1.9):
DMPC = 1,2-Dimyristoyl-sn-
glycero-3-phosphocholine;
SA = l-glutamic acid, N-(3-
carboxy-1-oxopropyl)-, 1,5-
dihexadecyl ester);
IVadministration tomaleWistar rats (2
mg/kg)
Selectively delivered to macrophages in
spleen and bone marrow;
Potential intravenous delivery system
for antioxidant and anti-inflammatory
therapies
[152]
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Curcumin formulations Components Method of application Indications/remarks Ref.
PEG-DSPE = (1,2-distearoyl-
sn-glycero-3-
phosphoethanolamine-N-[monomethoxy
poly(ethylene glycol) (5000)]
-t-butyl alcohol/benzene, (1/1,v/v)
-physiological saline 70 mg/mL;
Lipid-nanospheres:
-curcumin þ soybean oil
(10 mg/mL)
-DMPC/SA/PEG-DSPE
(10/1/0.06, molar ratio)
þ soybean oil (280 mg/mL)
-2.5% glycerin solution
Liposomal curcumin -10:1 (w/w)-total lipids:curcumin;
Lipids:
-1,2-dimyristoyl-sn-glycero-3-
phosphocholine/1,2-dimyristoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (sodium salt) or a
pegylated version of
1,2-dimyristoyl-sn-glycero-3-phosphocholine/
cholesterol/1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy-
(polyethylene glycol)-2000]
IV administration to female
athymic nu/nu mice (human
colorectal tumor xenografts
in nude mice models)
(liposomal curcumin
40 mg/kg, oxaliplatin
5 mg/kg);
in vitro studies (LoVo and Colo205
cells)
Equivalent or greater growth-inhibitory and
apoptotic effects with oxaliplatin both
in vitro and in vivo in colorectal cancer
[153]
Self nanoemulsion of
curcumin and silymarin
-15 mg curcumin
-25 mg silymarin
- 1 g oil phase
(glycerin monooleate; Tween 20:PEG 400,
1:8:1 ratio)
- deionized water:oil phase, 5:1
(self-nanoemulsifying method)
Stability study Higher stability of silymarin and curcumin in
comparison with a conventional emulsion
Efficient drug delivery system
[154]
Table 1. Curcumin formulations.
An Update On Natural Compounds and Their Modern Formulations for the Management of Malignant Melanoma
http://dx.doi.org/10.5772/67647
229
Silymarin formulations Components Method of application Indications/remarks Ref.
Self-microemulsifying drug delivery
system (SMEDDS)
-10% ethyl linoleate
-30% Cremophor EL
-60% ethyl alcohol (% w/w)
Oral administration to male
mongrel dogs (50 mg/kg, single
dose)
3 months stability;
Faster release;
2.2-fold enhanced oral absorption, increased
bioavailability;
Indication: Oral administration of silymarin
[155]
Semisolid dispersion binary system using
Gelucire 44/14 as carrier
Silymarin:Gelucire
1:1 and 1:3 (w/w)
Oral administration to New
Zealand albino rabbits (280 mg/kg)
Linear increase of silymarin solubility and
dissolution degree depending on the career
concentration -> significant superior
pharmacokinetic profile
[156]
Solid dispersion of silymarin with a
hydrophilic polymer (HPMC E15 LV)
-silymarin powder
-78.7 % silymarin
-20.3 % silybin
-isosilybin)
-HPMC E 15LV
(1:1, 1:3, and 1:5 (w/w))
(kneading, spray drying and
co-precipitation method of
preparation)
Influence of preparation
methodology of solid dispersions
of silymarin
Co-precipitation method revealed the best
soluble and stable amorphous solid
dispersion;
The best results: 1:1 for the kneading method
and 1:3 for other methods;
Increased silymarin dissolution: co-
precipitation (2.5-fold) > spray drying (1.9-
fold) > kneading (1.5-fold);
Mean dissolution time: 8.3 min for co-
precipitation, 14.2 min for spray drying and
17.4 min for kneading
[157]
Silymarin loaded chitosan nanoparticles -40 mg chitosan
-10 mg silymarin
- 2% acetic acid solution
- 1mL ethanol
-10 mg sodium
tripolyphosphate
-1M NaOH 1M/0.1M HCl
(for pH adjustment)
-5% D-mannitol solution (ionic
gelation method of preparation)
Oral administration to Swiss
Albino mice (CCl4 hepatotoxicity
model), 50 mg/kg
Sustained release
Improved pharmacological activity
[158]
Solid dispersion and silica nanoparticles
of silymarin with slow-release matrix
material and release enhancer
- silymarin solid
dispersion:
-silymarin:povidone
K30:soy bean lecithin:
acrylic resin IV:
1–3:0.3–0.8:0.2–0.5 (w:w)
-silymarin solid dispersion:
Oral administration in Beagle dogs Continuous controlled release for 72 h;
Half-life 2.3 times longer
[159]
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Silymarin formulations Components Method of application Indications/remarks Ref.
silymarin-loaded silica
nanoparticles:slow-release matrix
material:release enhancer:
0.5–1.25:0.1–0.3:0.1–0.3 (w/w)
Silymarin glyceryl monooleate/
Poloxamer 407 liquid crystalline matrices
-20 g glyceryl monooleate
-2.4 g poloxamer 407
-silymarin 2%, 4%, 8% (melting/
congealing method of preparation)
Oral capsules administered to
Beagle dogs
(14.4 mg/kg silybin)
In vitro limited release of silymarin;
3.46-fold enhancement in oral bioavailability
in comparison with Legalon® (as a result of
the liquid crystalline phase formed in the
digestive tract)
[160]
Silymarin-loaded liquid proliposome - 1.0 g silymarin
-10.0 g soy lecithin
- 5.0 g cholesterol
- 0.5 g sodium oleate
-100.0 mL propylene glycol simple
dissolving process)
Oral administration to Kunming
mice (hepatitis experimental
models ; 75, 150, or 300 mg/kg)
Improved bioavailability and
hepatoprotection;
Efficient oral drug-delivery system for
silymarin
[161]
Liposomal lecithin-based carrier system
of phytosomal silymarin
-lecithin:cholesterol 6:1
(maximum entrapment-55%)
(film hydration method of
preparation)
In vitro study on Chang liver cells;
Oral administration to Wistar rats
3.5-fold enhanced oral bioavailability;
Higher hepatoprotective and anti-
inflammatory effects in comparison with a
silymarin suspension
[162]
Bile salt (sodium deoxycholate)
containing liposomes of silymarin
-ethanol:dichloromethane (12/13, v/
v)
-liposomes 20 mg/mL different
methods
of preparation: thin-film dispersion,
reversed-phase evaporation,
supercritical fluid technology)
Oral administration to male Wistar
rats (20 mg/kg)
Supercritical fluid technology -> adequate
for liposomes preparation
(the best stability of liposomes, the highest
entrapment efficiency and drug loading, the
smallest particle dimension);
Enhanced in vitro drug release;
Increased oral bioavailability
[163]
Table 2. Silymarin formulations.
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Paclitaxel formulations Components Method of application Indications/Remarks Ref.
Paclitaxel
(microemulsion/Taxol®)þ
silymarin
-Taxol®
-paclitaxel microemulsion
-silymarin
(insufficient data)
Oral administration to rats:
-Taxol®
þ10–20 mg/kg
silymarin;
-paclitaxel
microemulsion
þ20 mg/kg
silymarin
Silymarin association increased the oral
bioavailability of paclitaxel;
The highest absolute bioavailability (19%) -> for
silymarin þ paclitaxel microemulsion;
Faster absorption for paclitaxel microemulsion
compared to Taxol®
[164]
Paclitaxel (nanoemulsion) þ
curcumin
-paclitaxel nanoemulsion
-curcumin
(insufficient data)
Oral administration to SKOV3 tumor-
bearing nu/nu mice
(50 mg/kg
curcumin
þ20 mg/kg
paclitaxel)
5.2-fold increased oral relative bioavailability and
anti-tumor activity of paclitaxel (3.2-fold enhanced
accumulation in the tumor tissue)
[165]
Paclitaxel (Genetaxyl®) þ
cyclosporin A
Genetaxyl®
(paclitaxel 6 mg/mL)
þ cyclosporin A;
Genetaxyl®:
-20% (v/v) Cremophor EL
Genaxol®:
-50% (v/v) Cremophor EL
Oral administration to cancer patients
(60/120/180 mg/m2) þoral cyclosporin
A, 10 mg/kg
IV: 175 mg/m2,
3 h infusion
Less than proportional increase in systemic
exposure with increasing doses;
Limited paclitaxel bioavailability by micellar
entrapment;
Cremophor
EL ↓ concentration:
-↓ median time to peak
concentration;
-↑ absorption of
paclitaxel;
-↑ metabolism of
paclitaxel
[166]
Paclitaxel þ Cremophor EL Taxol®:
Paclitaxel in Cremophor EL –
dehydrated ethanol (1:1, v/v)
Intraperitoneal administration to
cancer patients
↓ Plasma concentration and bioavailability;
Prolonged peritoneal activity
[167]
Crystalline nanosuspension -paclitaxel (20 mg/mL):
-0.1% (w/w) Cremophor EL in
phosphate saline
IV administration to tumor bearing
xenograft female
SCID-beige mice
(20 mg/kg)
Weaker antiproliferative effects than the
Cremophor standard formulations
[168]
Self micro emulsifying oily
formulations (SMEOFs)
þcyclosporine A
Paclitaxel 1.5% (% w/v):
-paclitaxel 1.5 %
-vitamin E 5.00%
-Oral administration to wild-type and
P-glycoprotein knockout mice [169];
-oral administration to humans [170]
Satisfying oral bioavailability -> the systemic
exposure and oral bioavailability of paclitaxel was
comparable to Taxol® (40%);
[169],
[170]
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Paclitaxel formulations Components Method of application Indications/Remarks Ref.
-TPGS 29.95%
(d-alpha-tocopheryl
polyethylene glycol 1000
succinate)
-tyloxapol 33.05%
-ethanol 30.5%
Paclitaxel 3%
(% w/v):
-paclitaxel 3.0%
-vitamin E 5.0%
-TPGS 29.45%
-tyloxapol 32.55%
-ethanol 30%
Higher dose of paclitaxel->less effective uptake
(saturation of the first-pass metabolism);
SMEOF = suitable vehicle for oral administration
of paclitaxel associated with cyclosporine A
Supersaturable self-emulsifying
drug delivery system of paclitaxel
(S-SEDDS)
containing HPMC (precipitation
inhibitor);
þcyclosporine A
-lack of data Oral administration to male Sprague-
Dawley rats
(10 mg/kg
paclitaxel;
5 mg/kg
cyclosporine A)
5-fold higher oral bioavailability,
10-fold higher maximum concentration for S-
SEDDS formulation compared to Taxol®;
Association of cyclosporin A=> further increase in
oral bioavailability;
Slow crystallization of paclitaxel (in vitro dilution)
[171]
Solid-nanoemulsion
preconcentrate
(surfactant-co-surfactant system
based on Tween 20 and PEG)
Nanoemulsion preconcentrate:
-50 mg paclitaxel
- 1 mL of different
combinations of oil, surfactant,
and cosurfactant;
Optimized formulation:
oil:surfactant:cosurfactant
(µL) - 175:350:175;
Nanocarrier:
-Oil:
-propylene glycol
monocaprylate/
glycerol monooleate,
4:1 (w/w),
-Surfactant:
-polyoxyethylene 20 sorbitan
monooleate/
polyoxyl 15 hydroxystearate,
1:1 (w/w),
Oral administration to Wistar albino
rats (10 mg/kg)
Increased oral bioavailability;
High cumulative in vitro drug release;
Significant antiproliferative effect on breast cancer
cell line MCF7
[172]
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Paclitaxel formulations Components Method of application Indications/Remarks Ref.
-Cosurfactant:
-diethylene glycol monoethyl
ether/ polyethylene glycol
300, 1:1( w/w)
Niosomal formulation:
Niosomes with nonionic surfactants
Organic phase:
-Span 40 (M) – 0.0475
-cholesterol (M) – 0.0475
-DCP (dicetyl phosphate) (M) –
0.005
-paclitaxel (mM) – 0.234
-chloroform (Ml) – 10;
Water phase:
-ultrapure water (mL) q.s. 10
(niosomes prepared through
film hydration method)
In vitro studies Diffusion controlled release;
Low toxicologic profile;
Gastrointestinal stability
Suitable formulation for oral drug delivery
[173]
Paclitaxel-loaded pegylated
ethosomes
-paclitaxel
-cholesterol
-PEG3350
-phosphatidylcholine
(1:6.5:9:28, w/w)
-deionized water and ethanol
99.4% (67.5:32.5, v/v)
(pegylated ethosomes
prepared by reverse phase
evaporation technique)
In vitro studies Longer half life, slower release rate;
4.5-fold increase in cytotoxicity on human
melanoma SK-MEL-3 cell line, in comparison with
the free drug;
Possible alternative to the conventional
therapy
[174]
Paclitaxel-loaded lipid
nanocapsules
(mg/g):
- 1.9 paclitaxel
- 51.9 Solutol®HS15
-842.6 water
- 90.7 Captex® 8000
- 8.1 Lipoid® S100-3
- 4.8 NaCl powder
Oral administration to male Sprague-
Dawley rats
(10 mg/kg)
3-fold higher oral bioavailability (same results for
Taxol®-verapamil
(=P-glycoprotein inhibitor) association);
Potential formulation to augment the oral
bioavailability of the drug, avoiding verapamil
association
[175]
Solid lipid nanoparticles surface-
modified with hydroxypropyl-β-
cyclodextrin (HPCD)
- 100 mg stearic acid
- 5 mg paclitaxel
-0.25 mL ethanol
- 75 mg lecithin
- 75 mg poloxamer 188
Oral administration to male Sprague-
Dawley male rats (25 mg/kg)
Oral administration:
-fast release of paclitaxel
(nearly complete
release);
-high cellular uptake by
[176]
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Paclitaxel formulations Components Method of application Indications/Remarks Ref.
- 3 mL distilled water
-HPCD (modified hot
sonication method of
preparation)
Caco-2 cells;
-high concentrations in
the lymph nodes
(increased
bioavailability);
Role of HPCD in reducing the nanoparticle size
and enhancing the solubility and dissolution of the
drug;
HPCD may inhibit P-glycoprotein;
Alternative formulation for oral administration of
the drug
Solid lipid nanoparticles (=specific
colloidal carriers)
-paclitaxel:
stearic acidþDPPG.NA –
1:10, 1:15, 1:20
(micro-emulsification
technique)
Female Swiss Albino mice
(7.5 mg/kg)
Increased anticancer effect;
Increased specificity on breast cancer cells (for 1:20
formulation);
Release profile delayed with the enhancement of
lipid concentration;
Entrapment efficiency, particle size and zeta
potential value raised as lipid concentration was
augmented
[177]
Solid lipid nanoparticles modified
with 2-hydroxypropyl-β-
cyclodextrin
- 5 mg paclitaxel
- 100 mg stearic acid
-0.25 mL ethanol
- 75 mg lecithin
- 75 mg poloxamer 188
- 400 mg HPCD
(hot-melted sonication
technique)
Intratumoral administration in female
BALB/c nude mice for evaluation of
antitumor activity
(10 mg/kg)
IV administration to male Sprague
Dawley rats for pharmacokinetic
study (5 mg/kg)
IV delivery:
-diminished burst release;
-low nephrotoxicity;
-prolonged
antiproliferative
activity, increased
absorption;
Intratumoral administration:
-high antitumor
efficiency (sustained
release, high cellular
uptake);
-reduced toxicity to
normal organs;
Potential therapeutic formulation for breast cancer
with reduced nephrotoxicity
[178]
Biocompatible and biodegradable
polymeric nanoparticles
Organic phase:
-1 mg paclitaxel
In vitro studies Initial burst release followed by 7-days sustained
release;
[179]
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Paclitaxel formulations Components Method of application Indications/Remarks Ref.
- PLGA – 2%, 3%, 4% (w/v)
(Poly(lactic-co-glycolic
acid))
-10 mL acetone;
Aqueous phase:
-PVA (polyvinyl alcohol)
1%, 3%, 5% (w/v)
(emulsification-solvent
diffusion method)
Higher antiproliferative activity on Caco-2-cell-
line when compared to blank nanoparticles but
similar to paclitaxel solution
Stabilized Pluronic micelles -lack of data
(solvent/evaporation
technique)
Oral/IV administration in rats/mice Prolonged gastrointestinal release;
High oral absorption;
Optimized pharmacokinetic profile after IV
administration;
Indication: delivery vehicles (carriers) for oral or
intravenous paclitaxel administration
[180]
Table 3. Paclitaxel formulations.
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Resveratrol formulations Components Method of application Indications/remarks Ref.
Liposomal formulation -DPPC (dipalmitoyl-
phosphatidylcholine)
-PEG2000-DSPE –poly(ethyleneglycol)-
distearoylphosphatidyl ethanolamine)
-cholesterol dissolved in ethanol,
1.85:0.15:1 (molar ratio)
-resveratrol (maximum incorporation):
~5 mg/µmol of total lipid
(equivalent to 10 mg/µmol total lipids
added).
IV administration
to nude Balb/c female mice
(murine tumor model); 5 mg/
kg
Inhibition of tumor growth by 70%;
Improved chemical stability (prevention of
inactivating cis-trans isomerization)
[181]
β-cyclodextrin-based
nanosponges (BNS) formulation
-1:5 and 1:10 (w/w)
resveratrol:BNS;
-1:2 and 1:4 (molar ratio)
cyclodextrin:cross- linker
(carbonyldiimidazole)/BNS
In vitro studies Increased release and stability (in comparison with
plain drug);
Improved cytotoxicity on HCPC-I cell;
Good penetration in pigskin;
Better accumulation in rabbit mucosa.
Indication: buccal and topical administration
[182]
Monodisperse cyano-
functionalized porous
polymeric microspheres
- 4 g cyano-functionalized porous
particles
-0.2 wt% Tween 20 aqueous solution
(86g)
-0.2 g resveratrol
- 10 g ethanol;
Cyano-functionalized porous particles:
a. Seed dispersion:
-0.50 g polystyrene
- 40 g 0.25 wt% sodium
lauryl sulfate in water/EtOH
(5/1, w/w) solution
(=SE solution);
b. CD (Chlorododecane) swelling:
-0.5 g 1-CD
- 10 g SE solution;
c. The second monomer swelling:
-7 g/5 g/2 g styrene
-1 g/3 g/6 g divinylbenzene
- 2 g acrylonitrile
-10 g toluene/heptane
(porogen): 0/100, 30/70,
In vitro studies Antioxidant activity preserved for 5 weeks [183]
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Resveratrol formulations Components Method of application Indications/remarks Ref.
60/40, 100/0 wt%
-0.1 g benzoyl peroxide
- 40 g SE solution;
d. Stabilization:
-50 g polyvinyl alcohol 5% solution
(seeded polymerization technique)
Encapsulation within yeast cell Lack of data In vitro studies Increased DPPH-radical scavenging activity;
Good stability, enhanced bioavailability (increased
solubility, sustained release)
[184]
Zinc pectinate beads Zinc acetate = cross-linking agent;
-cross-linking solution pH 1.5
-zinc acetate concentration 5% (% w/v)
-crosslinking time 0.5 h -drying at room
temperature
-pectin concentration 5% (% w/v)
-pectin to resveratrol ratio of 3:1
(ionotropic gelation method)
In vitro studies Better delayed release for zinc-pectinate beads than
calcium-pectinate beads;
Encapsulation of a great amount of resveratrol in zinc-
pectinate beads
[185]
Zinc-pectin-chitosan composite
microparticles
-pectin:resveratrol, 3:1
-1% chitosan
In vivo studies on rats Specific drug release in the colon [186]
Resveratrolþquercetinþcurcumin -quercetin
-resveratrol
-curcumin
(applied alone/in
combination, at 50 μM)
In vitro studies Increased oral absorption of resveratrol and curcumin,
without interfering with the absorption of quercetin
[187]
Table 4. Resveratrol formulations.
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